Overview

* Inovio Q3 2025 net loss widens to $45.5 mln, driven by non-cash warrant liabilities

* Operating expenses decreased to $21.2 mln from $27.3 mln in Q3 2024

Outlook

* Inovio projects cash will support operations into Q2 2026

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses due to lower costs for INO-3107 manufacturing and clinical studies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.87

Q3 Net -$45.50

Income mln

Q3 $21.20

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc ( INO ) is $7.50, about 71.7% above its November 7 closing price of $2.12

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)